News
Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic ...
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in ...
SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut ...
Elutia’s Roswell facility is FDA-registered as a medical device manufacturing establishment and has not experienced any delays, cost increases, or supplier issues related to the tariffs. The Company ...
Hosted on MSN26d
Elutia Inc. secures $15 million through stock and warrant saleSILVER SPRING, Md. - Elutia Inc. (NASDAQ:ELUT), a medical technology company with a current market capitalization of $111.29 million according to InvestingPro, disclosed today that it has ...
Elutia Inc. has announced the launch of a clinical study for EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices (CIEDs).
Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro or Planet Microcap representative or email IR@ ...
Short interest in Elutia Inc (NASDAQ:ELUT) increased during the last reporting period, rising from 47.25K to 65.03K. This put 0.25% of the company's publicly available shares short. Short interest ...
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams ...
SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ...
Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro or Planet Microcap representative or email ...
Elutia To Participate In Chardan’S Trending Issues In Drug Development Conference Series On April 29
A live and archived webcast of the fireside chat will be available in the“Investors” section of the Elutia website at . Elutia develops and commercializes drug-eluting biomatrix products to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results